Nanobiotix S.A

Guggenheim initiated coverage of Nanobiotix S.A. with a Buy rating and a $64 price target on September 15, centering its thesis on the company's Johnson & Johnson-partnered JNJ-1900. The analyst's focus is NANORAY-312, the pivotal Phase 3 study of JNJ-1900 in locally advanced head and neck cancer patients ineligible for platinum-based chemotherapy, with final Phase 3 data expected in the first half of 2027. Guggenheim said its recent key opinion leader checks and study analysis give the trial high odds of success, though it framed that as the firm's assessment rather than an established probability. Nanobiotix entered a global licensing agreement with Johnson & Johnson in 2023 for JNJ-1900, formerly NBTXR3, and J&J now serves as global sponsor of NANORAY-312; in May, J&J received FDA clearance for a protocol amendment that eliminated the planned interim analysis and moved the study to an earlier final analysis requiring fewer events, with no changes to endpoints, hazard ratios, or expected effect size. The approximately $2.6 billion J&J deal represents potential deal value rather than money already received, with significant portions tied to future development, regulatory, and sales milestones, and J&J is also evaluating the candidate in a Phase 1b program in platinum-eligible head and neck cancer and a Phase 2 program in stage 3 unresectable non-small cell lung cancer.

Nanobiotix reported its first half 2026 operational and financial results, disclosing €110.9 million in cash and cash equivalents as of June 30, 2026, up from €52.8 million at December 31, 2025, and said that balance will fund operations into 2029. The company strengthened its position through an oversubscribed global follow-on offering completed in May 2026 with the underwriters' over-allotment option fully exercised, bringing total gross proceeds to approximately €86 million. Revenue and other income fell to €5.6 million for the six months ended June 30, 2026, from €26.6 million a year earlier, mainly because the first half of 2025 included a one-off non-cash positive revenue impact of €21.2 million tied to the transfer of NANORAY-312 study sponsorship to Johnson & Johnson. R&D expenses declined to €12.7 million from €14.5 million, SG&A expenses eased to €10.8 million from €11.3 million, and net loss attributable to common shareholders widened to €34.3 million, or €0.70 basic loss per share, from €5.4 million, or €0.11 basic loss per share. On the clinical side, full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study of JNJ-1900 (NBTXR3) in inoperable, locoregionally recurrent non-small cell lung cancer amenable to re-irradiation showed a one-year locoregional control rate of 79%, one-year local progression-free survival of 61% and one-year overall survival of 70% at a median follow-up of 12 months, with all 24 patients completing treatment with no dose-limiting toxicities and no Grade 3 or higher related adverse events. The Johnson & Johnson-led Phase 2 CONVERGE study in Stage 3 unresectable NSCLC showed an overall response rate of 85.7% and a complete response rate of 57.1% in 7 patients at ESTRO 2026, and the U.S. FDA cleared a protocol amendment to the Johnson & Johnson-led Phase 3 NANORAY-312 study in locally advanced platinum-ineligible head and neck cancer that eliminated the previously planned interim analysis and moved the final analysis to fewer events conducted sooner.

Nanobiotix reported €42.1 million in cash and cash equivalents as of March 31, 2026, which it expects will fund operations into 2029. The company completed a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million, including pre-funded warrants to accelerate development of its other platforms. New data from Part 1 of the Johnson & Johnson-sponsored Phase 2 CONVERGE study evaluating JNJ-1900 for Stage 3 inoperable non-small cell lung cancer were presented at the 2026 annual European Society for Radiotherapy and Oncology. The FDA accepted a protocol amendment to the ongoing pivotal J&J-sponsored NANORAY-312 study, eliminating a previously planned interim analysis and modifying the final analysis to include fewer events and be conducted sooner.